Therapeutic Areas Doctors & Pharmacists

• With the Genuair^® products, consisting of Bretaris^® Genuair^® (aclidinium bromide) and Brimica^® Genuair^® (aclidinium bromide/formoterol fumarate), we offer a continuous therapy for COPD patients who benefit from a 2x daily inhalation.

AT-WEB-09-05-2023

Allergology

Abnormal and specific reactions of the immune system to allergens are becoming more common, creating an increasing need for drug treatment of allergies. Allergic rhinitis (AR), a symptomatic disease of the nose triggered by IgE-mediated inflammation of the nasal mucosa after allergen exposure, is a common comorbidity of asthma and contributes to its development and severity, can also be well treated.¹

A. Menarini Pharma GmbH offers suitable therapies for different patient profiles:

• With the anti-allergic Olisir^®* (Bilastin), a fast-acting and well-tolerated preparation is available, which provides allergy patients with good symptom relief² and is available over the counter³.
• The nasal spray Ryaltris™** (mometasone furoate/ olopatadine) for allergic rhinitis not only effectively controls the classic symptoms of allergic rhinitis, such as sneezing, nasal itching, nasal congestion and rhinorrhea ^4-6 , but also improves patients' quality of life during short- ^4,5 and long-term ⁶ use.

    * Symptomatic treatment of allergic rhino conjunctivitis (seasonal and perennial) and urticaria. Olisir^® is used in adults and 
       adolescents (from 12 years of age). 

    ** RYALTRIS^TM nasal spray is used in adults and adolescents aged 12 years and over for the treatment of moderate to severe
        nasal symptoms of allergic rhinitis. The usual recommended dose is two sprays in each nostril twice a day (morning and
        evening). 

References: 1 World Allergy Organization (2005). In-depth review of allergic rhinitis. [online] (last updated October 2020). Available at: https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/in-depth-review-of-allergic-rhinitis [accessed 31.05.2023]; 2 Horak F et al. Inflamm Res. 2010 May;59(5):391–8; 3 Warenverzeichnis; 4 Gross GN, Berman G, Amar NJ, et al. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2019;122(6):630-638.e3; 5 Hampel FC, Pedinoff AJ, Jacobs RL, et al. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2019;40(4):261-272.; 6 Segall N, Prenner B, Lumry W, et al. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc 2019;40(5):301-31




AT-WEB-01-03-2025